Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries

(access-to-hepatitis-C-treatment/page/3060907/">http://www.aidsmap.com/France-to-provide-universal-access-to-hepatitis-C-treatment/page/3060907/) (accessed at 1 July 2016). Bouscaillou, 2014, Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment, Int J. Drug Policy, 25, 871, 10.1016/j.drugpo.2014.01.007 Center for Disease Analysis report, available at: http://centerforda.com/fact_files.htm (accessed at 1 July 2016). Centers for Disease Control and Prevention (CDC), 2012, Progress toward prevention and control of hepatitis C virus infection–Egypt, 2001-2012, MMWR Morb. Mortal. Wkly. Rep., 61, 545 Chidi, 2016, Economic and public health impacts of policies restricting access to hepatitis C treatment for Medicaid patients, Value Health, 19, 326, 10.1016/j.jval.2016.01.010 Deuffic-Burban, 2016, Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case, J. Viral Hepat., 10.1111/jvh.12546 Feeney, 2014, Antiviral treatment of hepatitis C, BMJ, 348, g3308, 10.1136/bmj.g3308 Gower, 2014, Global epidemiology and genotype distribution of the hepatitis C virus infection, J. Hepatol., 61, S45, 10.1016/j.jhep.2014.07.027 Graham, 2015, A path to eradication of hepatitis C in low- and middle-income countries, Antivir. Res., 119, 89, 10.1016/j.antiviral.2015.01.004 Health Consumer Powerhouse AB, 2012 Innes, 2015, Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?, Gut, 64, 1800, 10.1136/gutjnl-2014-308166 International Organization for Migration, 2013 Iyengar, 2016, Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis, PLoS Med., 13, 10.1371/journal.pmed.1002032 Linas, 2015, The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann. Intern. Med., 162, 619, 10.7326/M14-1313 Marcellusi, 2016, Early treatment in HCV: is it a cost-utility option from the Italian perspective?, Clin. Drug Invest., 36, 661, 10.1007/s40261-016-0414-y Ozaras, 2015, Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe, Clin. Microbiol. Infect., 21, 1027, 10.1016/j.cmi.2015.07.002 Stvilia, 2006, Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T'bilisi, Republic of Georgia, J. Urban Health, 83, 289, 10.1007/s11524-006-9032-y Surveillance and prevention of hepatitis B and C in Europe. Technical report, available at: http://ecdc.europa.eu/en/healthtopics/hepatitis_C/Pages/index.aspx#sthash.8hClPwH0.dpuf (accessed at 1 July 2016). Webster, 2015, Dusheiko GM, Hepatitis C. Lancet, 385, 1124 WHO guidelines, available at: http://www.who.int/hepatitis/strategy2016-2021/en (accessed at 1 July 2016). World Bank classification of countries by economy, available at: http://data.worldbank.org/about/country-and-lending-groups (accessed at 1 July 2016). Yilmaz, 2016, Barriers to access to hepatitis C treatment, J Infect Dev Ctries, 10, 308, 10.3855/jidc.7849 Zoulim, 2015, Hepatitis C virus treatment in the real world: optimising treatment and access to therapies, Gut, 64, 1824, 10.1136/gutjnl-2015-310421